ImageneBio Highlights IMG-007 in Corporate Update

ImageneBio updated its corporate presentation, emphasizing the potential of IMG-007 for treating atopic dermatitis. The product features receptor targeting, T cell-preserving properties, and extended half-life. ImageneBio is well-funded with commercialization rights for IMG-007. Analysts rate IMA stock as a Buy with a $30 target, while Spark rates it Neutral due to financial challenges. ImageneBio, established in July 2025, focuses on autoimmune and inflammatory disease treatments.

ImageneBio | 10-Q: FY2025 Q3 Revenue: USD 0

ImageneBio | 8-K: FY2025 Q3 Revenue: USD 0

ImageneBio reports Q3 cash position of $142.6 million and increased R&D expenses

ImageneBio Inc. reported a Q3 cash position of $142.6 million, significantly up from $12.1 million at the end of 2024, following its merger with Ikena Oncology and a $75 million private placement. R&D expenses rose to $15.6 million, while general and administrative expenses increased to $11 million. The net loss for the quarter was $24.8 million, compared to $3.2 million in the previous year, largely due to merger-related costs. The company also announced protocol amendments for its Phase 2b ADAPTIVE study and upcoming data presentations.

ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team

ImageneBio reported its Q3 2025 financial results, highlighting $142.6 million in cash and equivalents. The company announced a protocol amendment for its Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis to optimize study design. The leadership team was strengthened with new appointments, including Dr. Kristin Yarema as CEO. Upcoming presentations at the Inflammatory Skin Disease Summit will showcase novel data on IMG-007's efficacy in alopecia areata and atopic dermatitis. Topline data from the ongoing trial is expected in 2027.